Company: RGNT
Filing Date: 2025-05-05
Form Type: F-1/A
Source: 0001213900-25-039589
Chunk: 187

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-05
Form: F-1/A
Chunk 187
---
, to the fullest extent permitted by Israeli law, from
liability to us for damages caused to us as a result of a breach of duty of care, and undertaking to indemnify them to the fullest extent
permitted by the Israeli law. The insurance is subject to our discretion depending on its availability, effectiveness and cost. Effective
as of the consummation of this offering, the maximum amount set forth in such agreements is (1) with respect to indemnification in connection
with a public offering of our securities, the gross proceeds raised by us and/or any selling shareholder in such public offering, and
(2) with respect to all permitted indemnification, the greater of (i) an amount equal to 25% of our shareholders’ equity, based
on our most recent financial statements made publicly available before the date on which the indemnity payment is made and (ii) $20 million.
In the opinion of the SEC, indemnification of directors and executive officers for liabilities arising under the Securities Act however,
is against public policy and therefore unenforceable.

A shareholder’s investment
may be adversely affected to the extent we pay the costs of settlement and damage awards against officers and directors pursuant to these
indemnification provisions. We believe that these provisions, the insurance and the indemnity agreements are necessary to attract and
retain talented and experienced officers and directors.

<div align='center'>110</div>

Equity Incentive Plan

2009 Option Plan

We adopted our 2009 Option
Plan, or 2009 Plan, in January 2009 and it is scheduled to expire in December 2029. The 2009 Plan provides for the grant of options to
our employees, directors, officers, consultants, advisors, suppliers, and any other person or entity whose services are considered valuable.
As of November 1, 2024, options to purchase 79,290 Ordinary Shares were outstanding and 158,925 additional Ordinary Shares available for
future issuance. Of such outstanding options, options to purchase 79,290 Ordinary Shares were vested as of December 31, 2023, with an
exercise price of $ 3.97 per share.

The 2009 Plan provides for
options to be granted at the determination of our board of directors (which is entitled to delegate its powers under the 2009 Plan to
our compensation committee) subject to applicable laws. Upon termination of employment for any reason, other than in the event of death
or disability or for